Latest News

Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
Gemcitabine-BCG shows early promise in BCG-exposed NMIBC

December 6th 2024

CR rate was 98% (39/40) at 3 months, 94% at 6 months (34/36), and 81% at 12 months (21/26).

FDA logo
FDA grants priority review to durvalumab for muscle-invasive bladder cancer

December 6th 2024

Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
SunRISe-1 data point to safety, tolerability of TAR-200 in NMIBC

December 6th 2024

3d rendered illustration - bladder cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
ADVANCED-2 data demonstrate safety, efficacy of TARA-002 in NMIBC

December 5th 2024

Human urinary bladder | Image Credit: © magicmine - stock.adobe.com
BOND-003: Cretostimogene yields high CR rate, is well tolerated in NMIBC

December 5th 2024

Latest Videos

Latest News

© 2024 MJH Life Sciences

All rights reserved.